All posts by Sana Shakir

FDA Guidance Details Exemptions and Exclusions from Certain Drug Supply Chain Security Act Requirements Due to COVID-19 Public Health Emergency

On April 30, 2020, the U.S. Food and Drug Administration (“FDA”) published guidance clarifying the nature and scope of exemptions and exclusions to certain requirements under the Drug Supply Chain Security Act (“DSCSA”) triggered by the COVID-19 public health emergency. By waiving certain requirements under the DSCSA for the duration […]

Nevada Issues over $17 Million in Fines Against Drug Manufacturers for Failing to Comply with Drug Pricing Transparency Law

Earlier this month, the Nevada Department of Health and Human Services (DHHS) imposed $17.4 million in fines on 21 drug manufacturers for failing to comply with the state’s drug pricing transparency law related to essential diabetes drugs (EDD). This is the first public enforcement action by DHHS in connection with […]

Texas Becomes 50th State to Recognize Physician-Patient Relationship Established through Telemedicine

On May 27, Texas Governor Greg Abbott signed S.B. 1107 (the “Bill”), making Texas the last state in the nation to allow for the establishment of a physician-patient relationship through a virtual visit. The recently passed legislation eases the regulations surrounding the delivery of telemedicine services in Texas, and has […]